Elanco Animal Health Incorporated (ELAN)

NYSE: ELAN · Real-Time Price · USD
14.90
-0.14 (-0.93%)
At close: Jul 11, 2025, 4:00 PM
14.65
-0.25 (-1.68%)
After-hours: Jul 11, 2025, 7:55 PM EDT
-0.93%
Market Cap 7.40B
Revenue (ttm) 4.43B
Net Income (ttm) 373.00M
Shares Out 496.65M
EPS (ttm) 0.75
PE Ratio 19.88
Forward PE 18.35
Dividend n/a
Ex-Dividend Date n/a
Volume 3,844,041
Open 14.84
Previous Close 15.04
Day's Range 14.78 - 15.02
52-Week Range 8.02 - 15.78
Beta 1.68
Analysts Buy
Price Target 15.33 (+2.89%)
Earnings Date Aug 7, 2025

About ELAN

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus... [Read more]

Sector Healthcare
IPO Date Sep 20, 2018
Employees 9,450
Stock Exchange NYSE
Ticker Symbol ELAN
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for ELAN stock is "Buy." The 12-month stock price target is $15.33, which is an increase of 2.89% from the latest price.

Price Target
$15.33
(2.89% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

GREENFIELD, Ind. , July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025.

1 day ago - PRNewsWire

Elanco's dog flu vaccine gets USDA nod

Elanco Animal Health said on Wednesday the U.S. Department of Agriculture (USDA) has approved its canine flu vaccine, which offers dogs protection against serious respiratory disease.

2 days ago - Reuters

Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection

TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8. 100% virus neutralization against 33 current field isolates.1 Unlike cu...

2 days ago - PRNewsWire

Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001

Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providi...

9 days ago - PRNewsWire

Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise

After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated ELAN appears to be turning a corner.

15 days ago - Benzinga

Elanco Releases 2024 Impact Report and Introduces New Framework

GREENFIELD, Ind. , June 26, 2025 /PRNewswire/ -- Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, n...

15 days ago - PRNewsWire

Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)

Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind. , June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today th...

4 weeks ago - PRNewsWire

Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief. Data reveals that nearly 9 in 10 dogs in the U.S. are "itch...

5 weeks ago - PRNewsWire

Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

GREENFIELD, Ind. , May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Of...

6 weeks ago - PRNewsWire

Elanco to Participate in the Upcoming Investor Conferences

GREENFIELD, Ind. , May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.

2 months ago - PRNewsWire

Elanco: Deleveraging Takes Time

Elanco's shares have been pressured due to pipeline delays and debt from the Bayer acquisition, causing cautious optimism despite recent valuation resets. The company focuses on animal health, with ba...

2 months ago - Seeking Alpha

Elanco Animal Health Incorporated (ELAN) Q1 2025 Earnings Call Transcript

Elanco Animal Health Incorporated (NYSE:ELAN) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Tiffany Kanaga - Head of Investor Relations Jeffrey Simmons - President and ...

2 months ago - Seeking Alpha

Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide

Elanco Animal Health Incorporated   ELAN reported first-quarter 2025 adjusted earnings per share of 37 cents. That's up 9% year over year.

2 months ago - Benzinga

Elanco Animal Health Reports First Quarter 2025 Results

Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results: Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growth Reported Net Income of $67 millio...

2 months ago - PRNewsWire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the ...

2 months ago - Accesswire

Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal

Elanco Animal Health Incorporated ELAN on Monday announced the sale of certain future tiered royalties and commercial milestones associated with Xdemvy (lotilaner ophthalmic solution) 0.25% for the hu...

Other symbols: BX
2 months ago - Benzinga

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

GREENFIELD, Ind. , May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEM...

Other symbols: TARS
2 months ago - PRNewsWire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the ...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Shareholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the ...

2 months ago - Accesswire

Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "t...

2 months ago - Accesswire

Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "t...

2 months ago - Accesswire

Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco

Sarat Sethi, Managing Partner at DCLA, joins CNBC's "Halftime Report" to detail his latest trades.

Other symbols: ZTS
2 months ago - CNBC Television

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "t...

2 months ago - Accesswire

Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease. Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionall...

2 months ago - PRNewsWire

Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "t...

2 months ago - Accesswire